-+ 0.00%
-+ 0.00%
-+ 0.00%

Veru to Present Enobosarm Data At ObesityWeek 2025 Highlighting Lean Mass Preservation And Fat Loss Selectivity

Benzinga·10/31/2025 12:44:07
Listen to the news

Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek 2025 taking place November 4-7, 2025, in Atlanta, Georgia.

Poster presentation name: Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing Semaglutide

Presenter: Steven B. Heymsfield, M.D., a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana

Session Date: Tuesday, November 4, 2025

Session Time: 7:30 pm - 8:30 pm Eastern Time

Session Room: Exhibit Hall A1

Oral presentation name: Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function

Presenter: Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru

Session Date: Friday, November 7, 2025

Session Time: 8:00 am - 8:15 am Eastern Time

Session Room: GWCC Building A: A411-A412